• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

553.48 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
March 18, 2024
 
Via Benzinga
News headline image
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗
March 17, 2024
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
News headline image
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring ↗
March 15, 2024
FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease.... 
Via Benzinga
News headline image
Why Is Geron (GERN) Stock Up 94% Today? ↗
March 15, 2024
Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing. 
Via InvestorPlace
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading
March 15, 2024
Via Investor Brand Network
News headline image
Madrigal Pharmaceuticals: Q4 Earnings Insights ↗
February 28, 2024
 
Via Benzinga
News headline image
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
March 15, 2024
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
Via Benzinga
News headline image
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday ↗
March 15, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported... 
Via Benzinga
Topics Stocks
News headline image
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today ↗
March 15, 2024
Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
March 15, 2024
 
Via Benzinga
News headline image
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗
March 15, 2024
Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
March 15, 2024
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
March 14, 2024
 
Via Benzinga
News headline image
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
March 14, 2024
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
News headline image
Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH ↗
March 14, 2024
The company hopes to be the first to the finish line with a treatment for MASH. 
Via Investor's Business Daily
News headline image
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. ↗
March 09, 2024
Good news could be in store for all three of these drugmakers. 
Via The Motley Fool
News headline image
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? ↗
March 05, 2024
This business could be on the cusp of making medical history. 
Via The Motley Fool
News headline image
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena ↗
February 26, 2024
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
News headline image
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street ↗
February 23, 2024
The company might have a bright future, but is now the right time to buy shares? 
Via The Motley Fool
News headline image
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug ↗
February 08, 2024
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. 
Via Investor's Business Daily
News headline image
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength ↗
February 06, 2024
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
February 06, 2024
 
Via Benzinga
News headline image
2 Rising Biotechs That Could Become the Next Novo Nordisk ↗
January 29, 2024
Each of these companies has a big market in its sights. 
Via The Motley Fool
News headline image
2 Stocks That Could Soar This Year: Are They Buys? ↗
January 22, 2024
They might perform well in 2024, but how will they do beyond that? 
Via The Motley Fool
News headline image
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development ↗
January 12, 2024
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
Via Benzinga
News headline image
3 Stocks That Could Be Monster Winners in 2024 ↗
December 30, 2023
Don't be surprised if these three stocks take off in the new year. 
Via The Motley Fool
News headline image
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
December 08, 2023
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings. 
Via Benzinga
News headline image
These 2 Stocks Could Be About to Soar: Are They Buys? ↗
December 07, 2023
One thing is for certain -- both of these companies are innovators. 
Via The Motley Fool
News headline image
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money ↗
November 30, 2023
These stocks just might have investors seeing double over the next few years. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap